David Lebowitz
Stock Analyst at Citigroup
(3.38)
# 965
Out of 4,915 analysts
112
Total ratings
52.5%
Success rate
2.81%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Buy | $88 → $103 | $75.58 | +36.28% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $33.79 | +12.46% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $11.39 | +93.15% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $47.70 | +40.46% | 5 | Jul 11, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $213 → $243 | $173.10 | +40.38% | 13 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $36.80 | +52.17% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $11.75 | -14.89% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $38.06 | +110.19% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.49 | +0.67% | 6 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $42.77 | +49.64% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $52.02 | -13.49% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $52.30 | +30.02% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $22.09 | +216.89% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $20.56 | +79.96% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $304.74 | +25.35% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $57.92 | +65.75% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $3.51 | +241.88% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $395.37 | -58.52% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $14.35 | +171.78% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $9.85 | +113.20% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $3.87 | +10,365.12% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.79 | +1,662.56% | 2 | Oct 12, 2021 |
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $75.58
Upside: +36.28%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $33.79
Upside: +12.46%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $11.39
Upside: +93.15%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $47.70
Upside: +40.46%
Ascendis Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $213 → $243
Current: $173.10
Upside: +40.38%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $36.80
Upside: +52.17%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $11.75
Upside: -14.89%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $38.06
Upside: +110.19%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.49
Upside: +0.67%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $42.77
Upside: +49.64%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $52.02
Upside: -13.49%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $52.30
Upside: +30.02%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $22.09
Upside: +216.89%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $20.56
Upside: +79.96%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $304.74
Upside: +25.35%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $57.92
Upside: +65.75%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $3.51
Upside: +241.88%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $395.37
Upside: -58.52%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $14.35
Upside: +171.78%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $9.85
Upside: +113.20%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $3.87
Upside: +10,365.12%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.79
Upside: +1,662.56%